1983

Passage of Orphan Disease Act that gave drug companies financial incentives to conduct research on these rare diseases, e.g., Gaucher’s disease, a lysomal disorder like Tay-Sachs for which only 30% carrying the gene ever manifest the disease, and for which an effective enzyme replacement therapy was approved by FDA in 1991 (Wailoo & Pemberton, 52-53).